Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715738 | 0.88 | KMT2A (0.53) | KMT2AALDH1A1ALOX12MAPTNPSR1 | |
| SCHEMBL8336337 | 0.87 | LPAR1 (0.55) | KMT2AALDH1A1ALOX12MAPTNPSR1 | |
| SCHEMBL6720018 | 0.85 | MEN1 (0.63) | KMT2AALDH1A1ALOX12MAPTNPSR1 | |
| SCHEMBL6825413 | 0.85 | MAPT (0.60) | KMT2AALDH1A1MAPTLMNATDP1 | |
| SCHEMBL6719552 | 0.85 | CYP1A2 (0.52) | KMT2AALDH1A1MAPTLMNAHTT | |
| SCHEMBL6717393 | 0.84 | ALDH1A1 (0.52) | KMT2AALDH1A1ALOX12MAPTNPSR1 | |
| SCHEMBL6715541 | 0.84 | ULK1 (0.50) | KMT2AALDH1A1ALOX12MAPTNPSR1 | |
| SCHEMBL6726995 | 0.84 | CRHBP (0.55) | KMT2AALDH1A1ALOX12MAPTLMNA | |
| SCHEMBL6718586 | 0.84 | SMN1; SMN2 (0.54) | KMT2AALDH1A1ALOX12MAPTNPSR1 | |
| SCHEMBL6727004 | 0.84 | MAPT (0.51) | KMT2AALDH1A1ALOX12MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022528-A2 | ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | SLC1A2, SLC1A1, SLC7A11 | KMT2A 1656/4885ALDH1A1 575/4885ALOX12 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.